Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07433673
Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC) (GAP Cemi)
A Phase 2 Single-arm Study of Cemiplimab, Added to Typical Chemotherapy (Gemcitabine, Cisplatin, Nab-paclitaxel) for Down-staging of Locally Advanced, Unresectable Biliary Tract Cancer
Sponsor: Columbia University
Conditions
Colon and Rectal Cancer
Interventions
Cemiplimab
Updated 1 time since 2026 Last updated: Feb 20, 2026 Started: Aug 31, 2026 Primary completion: Jan 31, 2028 Completion: Jan 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Colon and Rectal Cancer and is currently actively recruiting participants. Columbia University leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Columbia University
- Regeneron Pharmaceuticals
Data source: Columbia University
For direct contact, visit the study record on ClinicalTrials.gov .